Log in or Sign up for Free to view tailored content for your specialty!
Parkinson's Disease/Movement Disorders News
Aruna Bio secures US patent for exosome-derived neuroinflammation treatment
A Georgia-based biotechnology company has secured a U.S. patent for an exosome-based therapy to treat neuroinflammation that occurs in a range of neurodegenerative disease, according to the manufacturer.
Study: Dementia diagnosed later in Parkinson’s disease course
In two large trials of individuals with Parkinson’s disease, dementia occurred less frequently and later in the disease course than previously thought, according to new research published in Neurology.
Log in or Sign up for Free to view tailored content for your specialty!
Patient enrollment begins in study of novel light therapy for Parkinson’s disease
The first 100 patients have been enrolled in a clinical trial investigating a novel light therapy device intended to treat individuals with Parkinson’s disease, according to the manufacturer.
FDA approves Asleep Deep Brain Stimulation surgery for Parkinson’s, essential tremor
The FDA has approved Medtronic’s Asleep Deep Brain Stimulation surgery for individuals diagnosed with Parkinson’s disease as well as those with essential tremor, according to the manufacturer.
FDA approves Crexont extended-release capsules for Parkinson’s disease
The FDA has approved Crexont extended-release capsules for the treatment of Parkinson’s disease, according to the manufacturer.
Study: Body composition associated with neurodegenerative disease, brain aging
Body composition patterns associated with weight and fat distribution were strongly correlated with neurodegenerative disease and brain aging, mediated by cardiovascular disease, according to research published in Neurology.
Annovis secures US patent for buntanetap
Annovis Bio Inc. has secured a U.S. patent for methods of treating acute traumatic brain injuries with its lead drug candidate, an oral, small molecule neurotoxic protein inhibitor.
‘On’ time improvement significant at day 3 with combination therapy for Parkinson’s
Improvements in “on” time were observed as early as day 3 after treatment initiation with an investigational subcutaneous combination therapy for Parkinson’s disease, which also led to significant improvement by day 7, data show.
Antidopaminergics linked to worse cognitive, functional outcomes in HD at 6 years
Antidopaminergic medications were linked to worsening cognitive and functional effects that accelerate disease progression in Huntington’s disease, according to research presented at the Congress of the European Academy of Neurology.
FDA grants RMAT designation for stiff person syndrome therapy
The FDA has granted Regenerative Medicine Advanced Therapy designation to a Bay Area-based biopharmaceutical company for its autologous, fully human CD19 chimeric antigen receptor to treat those with refractory stiff person syndrome.
-
Headline News
Q&A: ‘We have to be worried’ about decline in measles vaccination
November 19, 20244 min read -
Headline News
Physicians encouraged to ‘embrace’ technology in practice management
November 19, 20245 min read -
Headline News
Artificial neural network has ‘excellent’ performance in predicting COPD exacerbations
November 20, 20242 min read
-
Headline News
Q&A: ‘We have to be worried’ about decline in measles vaccination
November 19, 20244 min read -
Headline News
Physicians encouraged to ‘embrace’ technology in practice management
November 19, 20245 min read -
Headline News
Artificial neural network has ‘excellent’ performance in predicting COPD exacerbations
November 20, 20242 min read